Concepts (145)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antibody-Dependent Cell Cytotoxicity | 8 | 2014 | 28 | 1.860 |
Why?
|
| HIV-1 | 10 | 2013 | 438 | 1.280 |
Why?
|
| HIV Antibodies | 5 | 2013 | 42 | 1.240 |
Why?
|
| HIV Infections | 9 | 2018 | 970 | 1.100 |
Why?
|
| Killer Cells, Natural | 7 | 2014 | 91 | 0.870 |
Why?
|
| HIV Envelope Protein gp120 | 3 | 2013 | 19 | 0.700 |
Why?
|
| Cytokines | 3 | 2018 | 347 | 0.650 |
Why?
|
| Cytotoxicity Tests, Immunologic | 3 | 2014 | 13 | 0.650 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2015 | 218 | 0.610 |
Why?
|
| Methamphetamine | 1 | 2015 | 48 | 0.500 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2014 | 6 | 0.490 |
Why?
|
| HIV Seropositivity | 2 | 2013 | 94 | 0.490 |
Why?
|
| Cryopreservation | 1 | 2014 | 24 | 0.490 |
Why?
|
| Asymptomatic Infections | 1 | 2013 | 2 | 0.480 |
Why?
|
| Substance-Related Disorders | 1 | 2015 | 104 | 0.480 |
Why?
|
| Cervix Uteri | 2 | 2004 | 38 | 0.470 |
Why?
|
| Viral Load | 7 | 2013 | 197 | 0.420 |
Why?
|
| C-Reactive Protein | 6 | 1994 | 125 | 0.400 |
Why?
|
| Immunity, Humoral | 1 | 2010 | 6 | 0.370 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 2002 | 90 | 0.350 |
Why?
|
| Saliva | 1 | 2006 | 53 | 0.290 |
Why?
|
| Lymphocyte Activation | 5 | 2008 | 209 | 0.260 |
Why?
|
| Inflammation | 2 | 2018 | 344 | 0.250 |
Why?
|
| Humans | 19 | 2018 | 29337 | 0.200 |
Why?
|
| Immunosenescence | 1 | 2018 | 4 | 0.170 |
Why?
|
| Fish Oils | 1 | 2018 | 5 | 0.170 |
Why?
|
| Antibodies, Viral | 1 | 1996 | 87 | 0.140 |
Why?
|
| Cytotoxicity, Immunologic | 4 | 1991 | 29 | 0.140 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2013 | 150 | 0.140 |
Why?
|
| Cell Line | 2 | 2014 | 298 | 0.130 |
Why?
|
| Intracellular Space | 1 | 2015 | 8 | 0.130 |
Why?
|
| Self Administration | 1 | 2015 | 36 | 0.130 |
Why?
|
| Spleen | 1 | 2015 | 51 | 0.130 |
Why?
|
| Cell Count | 1 | 2015 | 99 | 0.130 |
Why?
|
| Female | 9 | 2018 | 16197 | 0.130 |
Why?
|
| Animals | 3 | 2015 | 4552 | 0.130 |
Why?
|
| Disease Progression | 2 | 2013 | 787 | 0.120 |
Why?
|
| Chromium Radioisotopes | 1 | 2014 | 2 | 0.120 |
Why?
|
| Lysosomal-Associated Membrane Protein 1 | 1 | 2014 | 2 | 0.120 |
Why?
|
| CD56 Antigen | 1 | 2014 | 8 | 0.120 |
Why?
|
| Cell Degranulation | 1 | 2014 | 7 | 0.120 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2014 | 27 | 0.120 |
Why?
|
| Receptors, IgG | 1 | 2014 | 19 | 0.120 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2015 | 451 | 0.120 |
Why?
|
| Prospective Studies | 3 | 2006 | 1811 | 0.120 |
Why?
|
| Male | 7 | 2018 | 15621 | 0.120 |
Why?
|
| Dendritic Cells | 3 | 2008 | 56 | 0.120 |
Why?
|
| Rats | 1 | 2015 | 854 | 0.110 |
Why?
|
| Immunity, Cellular | 3 | 2007 | 65 | 0.110 |
Why?
|
| Disease Models, Animal | 1 | 2015 | 724 | 0.100 |
Why?
|
| Signal Transduction | 1 | 1994 | 482 | 0.100 |
Why?
|
| Middle Aged | 5 | 2018 | 9823 | 0.100 |
Why?
|
| Antibodies, Catalytic | 1 | 2010 | 1 | 0.090 |
Why?
|
| Cross Reactions | 1 | 2010 | 26 | 0.090 |
Why?
|
| AIDS Vaccines | 1 | 2010 | 14 | 0.090 |
Why?
|
| Host-Pathogen Interactions | 1 | 2010 | 22 | 0.090 |
Why?
|
| Antibodies, Neutralizing | 1 | 2010 | 27 | 0.090 |
Why?
|
| Adult | 4 | 2013 | 8601 | 0.090 |
Why?
|
| Toll-Like Receptor 8 | 1 | 2008 | 2 | 0.080 |
Why?
|
| Toll-Like Receptor 7 | 1 | 2008 | 5 | 0.080 |
Why?
|
| Quinolines | 1 | 2008 | 16 | 0.080 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2008 | 86 | 0.080 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2008 | 49 | 0.080 |
Why?
|
| Coccidioides | 1 | 1987 | 2 | 0.080 |
Why?
|
| Uterine Cervical Diseases | 1 | 2007 | 4 | 0.080 |
Why?
|
| Imidazoles | 1 | 2008 | 72 | 0.080 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2007 | 10 | 0.080 |
Why?
|
| Papillomavirus Infections | 1 | 2007 | 37 | 0.070 |
Why?
|
| Antibody Specificity | 1 | 2006 | 50 | 0.070 |
Why?
|
| Immunoglobulin A | 1 | 2006 | 19 | 0.070 |
Why?
|
| Lymphocytes | 1 | 1986 | 110 | 0.070 |
Why?
|
| CD4-CD8 Ratio | 1 | 2004 | 16 | 0.060 |
Why?
|
| RNA, Viral | 1 | 2004 | 148 | 0.060 |
Why?
|
| Anti-HIV Agents | 1 | 2004 | 169 | 0.060 |
Why?
|
| Sexual Behavior | 1 | 2002 | 66 | 0.050 |
Why?
|
| Immunity, Innate | 1 | 2002 | 90 | 0.050 |
Why?
|
| Cells, Cultured | 3 | 2008 | 676 | 0.050 |
Why?
|
| Biomarkers | 2 | 2018 | 689 | 0.050 |
Why?
|
| In Vitro Techniques | 2 | 1991 | 213 | 0.040 |
Why?
|
| Calcium | 2 | 1994 | 491 | 0.040 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2018 | 15 | 0.040 |
Why?
|
| Adolescent | 1 | 2004 | 2279 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 2 | 1991 | 260 | 0.040 |
Why?
|
| Midwestern United States | 1 | 2018 | 67 | 0.040 |
Why?
|
| Dietary Supplements | 1 | 2018 | 53 | 0.040 |
Why?
|
| Flow Cytometry | 2 | 2008 | 198 | 0.040 |
Why?
|
| Interferon-alpha | 2 | 2008 | 66 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2018 | 503 | 0.040 |
Why?
|
| HIV Seroprevalence | 1 | 1996 | 4 | 0.040 |
Why?
|
| Viremia | 1 | 1996 | 36 | 0.040 |
Why?
|
| Killer Factors, Yeast | 1 | 1994 | 1 | 0.030 |
Why?
|
| Cell Polarity | 1 | 1994 | 8 | 0.030 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1994 | 35 | 0.030 |
Why?
|
| Cross-Linking Reagents | 1 | 1994 | 15 | 0.030 |
Why?
|
| Granulocytes | 1 | 1994 | 23 | 0.030 |
Why?
|
| Cytoskeleton | 1 | 1994 | 51 | 0.030 |
Why?
|
| Proteins | 1 | 1994 | 72 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 1994 | 129 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 1991 | 108 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 1991 | 96 | 0.020 |
Why?
|
| Immunologic Memory | 1 | 2008 | 35 | 0.020 |
Why?
|
| Cyclooxygenase 2 | 1 | 2008 | 30 | 0.020 |
Why?
|
| Ligands | 1 | 2008 | 55 | 0.020 |
Why?
|
| Interleukin-12 | 1 | 2008 | 38 | 0.020 |
Why?
|
| Cytotoxins | 1 | 1987 | 5 | 0.020 |
Why?
|
| Interferons | 1 | 1987 | 13 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2008 | 201 | 0.020 |
Why?
|
| Interleukin-1alpha | 1 | 2007 | 4 | 0.020 |
Why?
|
| Polysaccharides, Bacterial | 1 | 1987 | 6 | 0.020 |
Why?
|
| Chemokine CCL4 | 1 | 2007 | 8 | 0.020 |
Why?
|
| Macrophage Inflammatory Proteins | 1 | 2007 | 9 | 0.020 |
Why?
|
| Protamines | 1 | 1987 | 6 | 0.020 |
Why?
|
| Antigens, CD1 | 1 | 2007 | 6 | 0.020 |
Why?
|
| Neoplasms, Experimental | 1 | 1987 | 10 | 0.020 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 1987 | 3 | 0.020 |
Why?
|
| Chemokine CCL3 | 1 | 2007 | 12 | 0.020 |
Why?
|
| HLA-DR Antigens | 1 | 2007 | 26 | 0.020 |
Why?
|
| HIV Core Protein p24 | 1 | 2007 | 29 | 0.020 |
Why?
|
| Chemokine CXCL10 | 1 | 2007 | 8 | 0.020 |
Why?
|
| Chemokines, CXC | 1 | 2007 | 5 | 0.020 |
Why?
|
| Complement System Proteins | 1 | 1987 | 15 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 1996 | 3273 | 0.020 |
Why?
|
| Papillomaviridae | 1 | 2007 | 29 | 0.020 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2007 | 10 | 0.020 |
Why?
|
| Chemokine CCL5 | 1 | 2007 | 17 | 0.020 |
Why?
|
| Interleukin-4 | 1 | 2007 | 35 | 0.020 |
Why?
|
| Lymphocyte Subsets | 1 | 2007 | 30 | 0.020 |
Why?
|
| Interleukin-10 | 1 | 2007 | 36 | 0.020 |
Why?
|
| Interleukin-2 | 1 | 2007 | 66 | 0.020 |
Why?
|
| Mucous Membrane | 1 | 2007 | 40 | 0.020 |
Why?
|
| Antibodies | 1 | 1987 | 65 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2007 | 109 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 2007 | 81 | 0.020 |
Why?
|
| DNA Replication | 1 | 1986 | 12 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2007 | 219 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2007 | 638 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2007 | 1939 | 0.010 |
Why?
|
| Mice | 1 | 1986 | 1607 | 0.010 |
Why?
|
| Aged | 1 | 2008 | 9448 | 0.010 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1991 | 16 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1991 | 32 | 0.010 |
Why?
|
| Base Sequence | 1 | 1991 | 134 | 0.010 |
Why?
|
| DNA | 1 | 1991 | 125 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 1991 | 246 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 1991 | 323 | 0.010 |
Why?
|